All In Biotech

Drug Trial Radar · NCT01537081

Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections

Randomized, Double-Blind, Double Dummy, Placebo-Controlled Study of the Safety and Efficacy Mucinex (2400 mg/d) and Immediate-Release Guaifenesin (800 mg/d) in the Treatment of Symptoms of Acute Upper Respiratory Tract Infections For 7 Days

Last checked: Nov 20, 2026Latest source record: Nov 14, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,810 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,810

Actual

Start

Sep 2011

Primary completion

Mar 2012

Study completion Jul 2012

Sponsor

Lead sponsor
Reckitt Benckiser LLCIndustry
Sponsor type
Industry
First posted
Feb 22, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is designed to meet regulatory requirement outside the US. The dosing regimen and assessments timepoints were dictated by immediate release (IR) guaifenesin (GGE) and do not match approved Mucinex labeling in the U.S. The purpose of this study is to determine whether Mucinex is effective and non-inferior as compared to placebo and immediate release guaifenesin in the treatment of symptoms of acute upper respiratory infections. This design was required based on EU regulatory guidance.

Conditions

  • Acute Upper Respiratory Tract Infection

Interventions

  • MucinexDrug

    Mucinex combines immediate-release (IR) and modified-release guaifenesin in a bilayer tablet. Each tablet was 600 mg of guaifenesin and taken by mouth with a full glass of water.

  • Immediate-release GuaifenesinDrug

    Each tablet was 200 mg of immediate-release (IR) guaifenesin and taken by mouth with a full glass of water.

  • PlaceboDrug

    Placebo tablets in two formulations to match either Mucinex or IR guaifenesin taken by mouth with a full glass of water

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Summary Scores on the SUM8 Daily Cough and Phlegm Diary Card On the Morning of Day 4Time frame: Day 4
  2. Summary Scores on the SUM8 Daily Cough and Phlegm Diary Card On the Morning of Day 5Time frame: Day 5

Locations

43 sites in 1 country. Site status is shown where the registry gives one.

  • Reckitt Benckiser Study Site

    Hoover, Alabama

  • Reckitt Benckiser Study Site

    Bell Gardens, California

  • Reckitt Benckiser Study Site

    Harbor City, California

  • Reckitt Benckiser Study Site

    Long Beach, California

  • Reckitt Benckiser Study Site

    Sacramento, California

  • Reckitt Benckiser Study Site

    San Francisco, California

  • Reckitt Benckiser Study Site

    San Luis Obispo, California

  • Reckitt Benckiser Study Site

    Colorado Springs, Colorado

  • Reckitt Benckiser Study Site

    Denver, Colorado

  • Reckitt Benckiser Study Site

    Daytona Beach, Florida

  • Reckitt Benckiser Study Site

    Edgewater, Florida

  • Reckitt Benckiser Study Site

    Largo, Florida

  • Reckitt Benckiser Study Site

    Chicago, Illinois

  • Reckitt Benckiser Study Site

    Normal, Illinois

  • Reckitt Benckiser Study Site

    Wichita, Kansas

  • Reckitt Benckiser Study Site

    Lexington, Kentucky

  • Reckitt Benckiser Study Site

    Metairie, Louisiana

  • Reckitt Benckiser Study Site

    New Orleans, Louisiana

  • Reckitt Benckiser Study Site

    Brighton, Massachusetts

  • Reckitt Benckiser Study Site

    Fall River, Massachusetts

  • Reckitt Benckiser Study Site

    Bellevue, Nebraska

  • Reckitt Benckiser Study Site

    Omaha, Nebraska

  • Reckitt Benckiser Study Site

    Omaha, Nebraska

  • Reckitt Benckiser Study Site

    Las Vegas, Nevada

  • Reckitt Benckiser Study Site

    Las Vegas, Nevada

  • Reckitt Benckiser Study Site

    Rochester, New York

  • Reckitt Benckiser Study Site

    Raleigh, North Carolina

  • Reckitt Benckiser Study Site

    Cincinnati, Ohio

  • Reckitt Benckiser Study Site

    Middleburg Heights, Ohio

  • Reckitt Benckiser Study Site

    Warwick, Rhode Island

  • Reckitt Benckiser Study Site

    Greer, South Carolina

  • Reckitt Benckiser Study Site

    Dakota Dunes, South Dakota

  • Reckitt Benckiser Study Site

    Franklin, Tennessee

  • Reckitt Benckiser Study Site

    Jackson, Tennessee

  • Reckitt Benckiser Study Site

    New Tazewell, Tennessee

  • Reckitt Benckiser Study Site

    Smyrna, Tennessee

  • Reckitt Benckiser Study Site

    Austin, Texas

  • Reckitt Benckiser Study Site

    Carrollton, Texas

  • Reckitt Benckiser Study Site

    Forth Worth, Texas

  • Reckitt Benckiser Study Site

    San Angelo, Texas

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.